These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 20045142

  • 1. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
    Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao JY, Chang SJ, Lin SR, Shing SJ, Chen HC.
    Metabolism; 2010 Aug; 59(8):1139-44. PubMed ID: 20045142
    [Abstract] [Full Text] [Related]

  • 2. Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus.
    Zhang KH, Huang Q, Dai XP, Yin JY, Zhang W, Zhou G, Zhou HH, Liu ZQ.
    J Clin Pharmacol; 2010 Sep; 50(9):1022-30. PubMed ID: 20498286
    [Abstract] [Full Text] [Related]

  • 3. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.
    Andrulionytè L, Zacharova J, Chiasson JL, Laakso M, STOP-NIDDM Study Group.
    Diabetologia; 2004 Dec; 47(12):2176-84. PubMed ID: 15592662
    [Abstract] [Full Text] [Related]

  • 4. Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes.
    Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH.
    Eur J Pharmacol; 2011 Dec 05; 671(1-3):1-6. PubMed ID: 21968139
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
    Blüher M, Lübben G, Paschke R.
    Diabetes Care; 2003 Mar 05; 26(3):825-31. PubMed ID: 12610044
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha gene polymorphisms in Korean women with polycystic ovary syndrome.
    Chae SJ, Kim JJ, Choi YM, Kim JM, Cho YM, Moon SY.
    Gynecol Obstet Invest; 2010 Mar 05; 70(1):1-7. PubMed ID: 20130411
    [Abstract] [Full Text] [Related]

  • 10. The peroxisome proliferator-activated receptor gamma coactivator-1 alpha gene (PGC-1alpha) is not associated with type 2 diabetes mellitus or body mass index among Hispanic and non Hispanic Whites from Colorado.
    Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM.
    Exp Clin Endocrinol Diabetes; 2007 Apr 05; 115(4):268-75. PubMed ID: 17479445
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Primary pioglitazone failure in Asian Indian diabetics is not related to common Pro12Ala polymorph of PPAR-gamma gene.
    Mathur SK, Rathore R, Chandra S, Sharma BB, Sharma L, Mathur P, Mathur M.
    Indian J Physiol Pharmacol; 2009 Apr 05; 53(2):175-80. PubMed ID: 20112822
    [Abstract] [Full Text] [Related]

  • 13. Association between peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene polymorphisms and type 2 diabetes in southern Chinese population: role of altered interaction with myocyte enhancer factor 2C.
    Zhang SL, Lu WS, Yan L, Wu MC, Xu MT, Chen LH, Cheng H.
    Chin Med J (Engl); 2007 Nov 05; 120(21):1878-85. PubMed ID: 18067759
    [Abstract] [Full Text] [Related]

  • 14. PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.
    Pei Q, Huang Q, Yang GP, Zhao YC, Yin JY, Song M, Zheng Y, Mo ZH, Zhou HH, Liu ZQ.
    Acta Pharmacol Sin; 2013 Feb 05; 34(2):255-61. PubMed ID: 23147557
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
    Andrulionyte L, Peltola P, Chiasson JL, Laakso M, STOP-NIDDM Study Group.
    Diabetes; 2006 Jul 05; 55(7):2148-52. PubMed ID: 16804087
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabet Med; 2010 Feb 05; 27(2):150-6. PubMed ID: 20546257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.